A great profile on my CRISPR QC-founder, Dr. Kiana Aran in the Tech Times!
Ross Bundy’s Post
More Relevant Posts
-
Anyone out in Boston this week, come by and talk to the team from CRISPR QC and see how we can significantly improve gene editing results at the Cell and Gene Therapy Summit!
We are proud to share that CRISPR QC is a sponsor at the Cell and Gene Therapy Summit in Boston, MA this week! It's been a fantastic opportunity for us to showcase our cutting-edge technology and solutions while engaging with leaders and innovators in the industry. #CellAndGeneTherapy #CRISPR #Biotech #Innovation #Healthcare #FutureTech #GeneEditing #Boston
-
-
#CRISPR is one of the fastest growing and hottest markets in the biotech sector, and despite recent economic headwinds is still going strong. Anyone with a unique offering to accelerate the pace, like CRISPR QC, is well positioned for success.
CRISPR Market to Grow $7.1 Billion by 2028 Download Sample PDF Report-https://lnkd.in/ddZq79mv The global CRISPR market in terms of revenue was estimated to be worth $3.4 billion in 2023 and is poised to reach $7.1 billion by 2028, growing at a CAGR of 15.6% from 2023 to 2028. Companies Working in the Market CRISPR QC CRISPR Therapeutics SNIPR Biome - A CRISPR Company Twist Bioscience Integrated DNA Technologies Beam Therapeutics Caribou Biosciences Chan Zuckerberg Biohub Network Inari Aldevron Sapio Sciences Benson Hill Inscripta, Inc. Arbor Biotechnologies Sherlock Biosciences KSQ Therapeutics, Inc. Innovative Genomics Institute Graphite Bio Cure Rare Disease Locus Biosciences, Inc. Namocell Miroculus Santa Cruz Biotechnology (SCBT) Applied StemCell VectorBuilder Discover Echo Inc. CellFE Kytopen Molecular Assemblies, Inc. Cellecta, Inc. BDG LifeSciences Mirimus Horizon Discovery John Innes Centre Intellia Therapeutics, Inc. Mammoth Biosciences Editas Medicine Arsenal Biosciences, Inc. Eurofins Genomics India Pvt Ltd. Polyplus now part of Sartorius
-
-
I was really glad to do this podcast with Karen Jagoda and discuss what's coming! Her podcast really tries to unpack the complex world of medicine and science and break it down for many people. #CRISPR as a therapy is coming, and people should be ready. The ability to modify DNA is so incredibly powerful as a tool, but the risks are also extremely high. That's why I was happy to discuss how CRISPR QC has the fortunate opportunity help deliver on the promise. Thanks to our #CRISPRChip technology our #graphene #biosensor that is the core of it, we are rapidly unlocking the mysteries of how #geneediting works. While today our focus is helping develop these new therapies, what is often missed is our own bodies have a role to play. Everyone's DNA is different, and so no therapy will ever be exactly the same. The kinds of pathways we can explore unlock the opportunity to figure out not just how our individual DNA can affect the results, but even have the data to figure out what to do about it. Think on that: real #PrecisionMedicine. That's what's possible with #CRISPR, and CRISPR QC will be making that happen.
We're featured on the Empowered Patient Podcast with Karen Jagoda! In this episode, Ross Bundy dives into how CRISPR QC is shaping the future of patient care and our vision to revolutionize CRISPR therapies. 🌟 Key Highlights: Advancements in CRISPR: Ross discusses the rapid progress of CRISPR gene editing technology and its potential to target rare genetic diseases, cancer, and other indications. CRISPR QC's Unique Solutions: Our CRISPR Analytics Platform helps add control to the gene editing process, ensuring precise and effective results. Improving CRISPR Workflows: Ross explains the challenges in targeting and controlling CRISPR edits and how our technology opens the "black box" of CRISPR chemistry to enable precise control for pharmaceutical companies. Vision for the Future: At CRISPR QC, we're working every day to improve the understanding and control of CRISPR, ultimately transitioning this new science into a robust, data-backed process. Tune in to hear Ross share insights on the current state of CRISPR and how CRISPR QC is paving the way for future breakthroughs in patient care. The full podcast episode can be found here: https://lnkd.in/gPWBNguZ
Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC
empoweredpatientradio.com
-
It's very exciting to have the contributions we're making to the #geneediting and #CRISPR community be recognized by Genetic Engineering & Biotechnology News. The vast majority of the gene editing workflow is long and laborious, which limits how many different combinations and factors can be identified to result in a successful edit. The implications of this are high cost therapies with real risk attached. The workflow we're bringing to the community allows for rapid evaluation in parallel of many #CRISPR designs, leading to a lower cost and better product overall.
We're featured on Genetic Engineering & Biotechnology News in a recent article that profiles the recent successes and future landscape of the CRISPR industry. With over 80 clinical trials worldwide and innovative solutions for genetic disorders, the future of CRISPR looks brighter than ever. 🌟 At CQC, we're harnessing the power of our CRISPR-Chip to help researchers push their incredible work forward. Our platform provides real-time insights to optimize CRISPR editing, reduce costs, and scale up gene editing efforts. What are your thoughts on the future of CRISPR? Let’s connect and discuss how we can drive innovation together! Full article below: https://lnkd.in/gPtPAyKm #CRISPR #GeneEditing #Biotech #Innovation #Healthcare #FutureTech #QualityControl #GEN
CRISPR 2.0: Kinder, Gentler, More Powerful Gene Editing
genengnews.com
-
This is a great lab at UCSD and also a CRISPR QC partner making real progress towards controlling mosquito populations, which had enor.ous human health impacts around the world.
Systems Engineering Consulting of Complex Radar, Sonar, Navigation and Satellite Comm Systems
Ranking the most #dangerous in terms of humans killed per year is the female #Anopheles #Mosquito which carries #Malaria. Scientists are developing safe technologies to stop the transmission of malaria by #geneticediting #mosquitoes that spread the parasite that causes the disease. Researchers at the University of California San Diego led by Professor Omar Akbari’s laboratory http://www.akbarilab.com/ have engineered a new way to genetically suppress populations of Anopheles gambiae, the mosquitoes that primarily spread malaria in Africa and contribute to economic poverty in affected regions. The new system targets and kills females of the A. gambiae population since they bite and spread the disease. #technology #students #development #university #science #school #africa Publishing July 5 in the journal Science Advances https://lnkd.in/gfAyUSkX, first-author Andrea Smidler, a postdoctoral scholar in the UC San Diego School of Biological Sciences, along with former master’s students and co-first authors James Pai and Reema Apte, created a system called Ifegenia, an acronym for “inherited female elimination by genetically encoded nucleases to interrupt alleles.” The technique leverages the #CRISPR technology to disrupt a #gene known as femaleless (fle) that controls sexual development in A. gambiae mosquitoes.
New Genetic Technology Developed to Halt Malaria-Spreading Mosquitoes
today.ucsd.edu
-
The Deal Scout is a great podcast talking about different types of investment and business deals out there. Meeting Joshua Wilson and having the chance to tell a bit of my own story starting both Cardea Bio (part of Paragraf®) and CRISPR QC, working with deep tech before it was cool like #graphene and #geneediting and what I found when building an extremely scientifically advanced company while not being a scientist myself was a good reflection on the last 11 years of my life. Thanks for giving me the chance to tell my story, and I hope my experiences can help others who decide to set out on the #entrepeneur path!
Podcast Host | Family Office | IPOs | Institutional Investor | Capital Market Advisor | Author | The Deal Scout | PIPE's, Bridges, SPAC's, M&A, Venture Capital and Private Equity | Executive Producer | Kingmaker
Raising Capital for your life science or deep tech company? In the latest episode of The Deal Scout, we take a deep dive into the motivations and strategies of serial entrepreneurs within the advanced sectors of deep tech and carbon nanomaterials. Joining me is Ross Bundy, a veteran entrepreneur, who shares his insights on maneuvering through the complexities of these forward-looking industries with significant growth potential. https://lnkd.in/eTUhVFju
Exploring the Entrepreneurial Journey in Deep Tech: Insights from Ross
thedealscout.com
-
I'm really looking forward to meeting so many different angel groups at the Innovation Funders Showcase by the Angel Capital Association. Angel investors are a key pillar in the American economy. They are the place where new companies go to get new funding, often when a company is early and still very high risk. While investing in a company, it is also usually a very personal thing for an angel investor to invest in your company, and the responsibility of us as founders to our angel investors is high. I knew every investor in my first company personally, and I know every investor in CRISPR QC personally. These summits are great as you can form those personal connections to critical to the investor/founder relationship. Thanks Keiretsu Forum Mid-Atlantic, Barry Etra and Howard Lubert for the sponsorship, and I'll see you all next week!
We're proud to be sponsored by Keiretsu Forum for the Innovation Funders Showcase at the 2024 Angel Capital Association (ACA) Summit! Join us at the ACA Summit in Columbus, Ohio from May 13-15, 2024, to see our groundbreaking work in action! All details below. #GeneEditing #Innovation #CRISPRQC #ACASummit2024 https://lnkd.in/gQPJUgXY
CRISPR QC to Showcase Advanced Gene Editing Solutions with Keiretsu Forum Sponsorship at ACA Innovation Showcase
newsroom.notified.com
